Sanofi, Formation Bio, and OpenAI have announced a groundbreaking collaboration to accelerate drug development through advanced AI-powered software. This partnership aims to streamline the drug development process, making it more efficient and effective, and ultimately bringing new medicines to patients faster.
Sanofi, one of the world's leading biopharmaceutical companies, will leverage its proprietary data to develop AI models in partnership with OpenAI and Formation Bio. This collaboration marks a significant milestone in Sanofi’s journey to become the first biopharma company powered by AI at scale.
Paul Hudson, CEO of Sanofi, emphasized the transformative potential of this partnership: "This unique collaboration is the next significant step in our journey to becoming a pharmace
New AI Browsers Want to Replace Chrome. It Won’t Be Easy
Mukundan Sivaraj
